We show that Big Pharma would not have to shift a single element of supply chain to the US and can mitigate most, if not all, of a 20% tariff on drugs, just by changing their transfer pricing strategy. In a scenario where the US corporation tax rate falls to 15% but tariffs are 20%, we show that Big Pharma profits would be unchanged, while the US government tax take would more than double. The losers would be low tax jurisdictions like Ireland, but they would get to keep their manufacturing base...
Two XPO Leaders Named 2025 Top Women to Watch in Transportation Olivia Raymond and Jamie Sheffield recognized for their leadership and impact in the freight transportation industry GREENWICH, Conn., March 31, 2025 (GLOBE NEWSWIRE) -- (NYSE: XPO), a leading provider of freight transportation in North America, announced today that senior director of engineering and the project management office Olivia Raymond and director of strategic business development Jamie Sheffield have been named “Top Women to Watch in Transportation” for 2025 by the Women in Trucking Association. This recognitio...
XPO Announces $750 Million Share Repurchase Authorization GREENWICH, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- (NYSE: XPO), a leading provider of freight transportation in North America, today announced that its Board of Directors has authorized the repurchase of up to $750 million of XPO’s common stock. The new repurchase plan replaces XPO’s previous share repurchase plan, authorized in February 2019, which had $503 million remaining as of March 26, 2025. The new repurchase plan is effective immediately and permits shares of common stock to be repurchased from time to time at managemen...
XPO Named One of America’s Most Innovative Companies by Fortune GREENWICH, Conn., March 26, 2025 (GLOBE NEWSWIRE) -- (NYSE: XPO), a leading provider of freight transportation in North America, today was named to Fortune’s list of America’s Most Innovative Companies for 2025. XPO is the only pure play LTL carrier on the list. Mario Harik, chief executive officer of XPO, said, “We’re proud to be recognized by Fortune as one of America’s most innovative companies. This distinction highlights our team's commitment to best-in-class customer service, the landmark expansion of our network and...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at . Information on accessing and registering for the webcast will be available at beginning today. Participants are advised to re...
Three XPO Leaders Named 2025 “Pros to Know” by Supply & Demand Chain Executive Magazine GREENWICH, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- (NYSE: XPO), a leading provider of freight transportation in North America, announced today that three of its leaders have been named 2025 “Pros to Know” by Supply & Demand Chain Executive Magazine (SDCE). This is the fifth consecutive year that XPO employees have been recognized by SDCE for their outstanding work in the freight transportation industry. This year’s recipients from XPO are: Maura Holcomb (Rising Star), vice president, enterprise sa...
Les déboires récents de quelques sociétés du secteur (déceptions de CagriSema de Novo, de l’anti-TIGIT de Roche ou investigations en Chine pour AZN) accompagnés de questionnements sur la politique US ont engendré un derating conduisant à une valorisation faciale attractive : PE 26e de 13.2x. Les publications annuelles des 6 large cap Pharma européennes ont été extrêmement rassurantes confirmant les attentes CT et LT du marché. Avec un BPA en croissance moyenne entre 2024 et 2028 de c10%, le PEG ...
The recent setbacks for some sector companies (disappointments over Novo Nordisk’s Cagrisema and Roche’s anti-TIGIT or the investigations in China for AZN) along with question marks over US policy have generated a derating leading to a nominally attractive valuations: P/E 2026e of 13.2x. The full-year earnings reports of the six European large cap pharma companies were extremely reassuring, confirming short- and long-term market expectations. With average expected EPS growth between 2024 and 202...
Given the macro backdrop & our evidence in this note that Pharma can sustain faster than expected growth for the next decade, we believe investors should add to their Pharma positions. 2025 is the biggest year for pipeline readouts in recent history and we expect this to catalyse a re-rating. We show that 1) Pipelines are very robust, 2) The market underestimates the size of the “monster” blockbusters that account for 14% of all drugs, 3) 15% of 2030 sales are “generic resistant” due to the moda...
XPO Provides North American LTL Operating Data for February 2025 GREENWICH, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- (NYSE: XPO), a leading provider of freight transportation in North America, today reported certain preliminary LTL segment operating metrics for February 2025. LTL tonnage per day decreased 8.1%, as compared with February 2024, attributable to a year-over-year decrease of 6.2% in shipments per day and a decrease of 2.0% in weight per shipment. Actual results for February 2025 may vary from the preliminary results reported above. Mario Harik, chief executive officer of XP...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 10:30 a.m. Eastern Standard Time. To listen to the webcast, visit our web site at . Information on accessing and registering for the webcast will be available at beginning today. The transcript and webcast replay of the discussion will be made available on our web site at within 24 hours after the end of the live discussion a...
Two Directors at Pfizer Inc sold/bought 19,764 shares at between 0.000USD and 25.650USD. The significance rating of the trade was 98/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.